Galapagos operates in the Commercial physical research sector. Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: R & D and Services. The R & D division develops medicines based on modes of action in several indications with unmet medical need, including diabetes, COPD, osteoarthritis, osteoporosis and rheumatoid arthritis. The Services division, offers a suite of target-to-drug discovery products and services to pharmaceutical and biotechnology companies, encompassing target discovery and drug discovery services through to delivery of pre-clinical candidates. The Company also forms strategic long-term alliances for the majority of its research programs with large pharmaceutical companies. As of December 31, 2010, Galapagos NV was, through its subsidiairies, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In our complete report available for purchase the company is compared to: Basilea Pharmaceutica Limited, Ablynx N.V. and Swedish Orphan Biovitrum AB.